使用SAS从血液样品中选择泛癌表观遗传生物标志物
Pan-Cancer Epigenetic Biomarker Selection from Blood Samples Using SAS
摘要:
目前癌症研究的一个关键焦点是发现癌症生物标志物,这些生物标志物可以更早地检测出癌症,并且对患者和医院都具有高准确性和更低的成本。血液样本长期以来一直被用作健康状况指标,但血液中的DNA甲基化特征在癌症研究中尚未得到充分重视。历史上,癌症的分析直接用患者的肿瘤或相关组织进行。这种分析允许医生诊断患者的健康和癌症状态;然而,医生必须观察某些症状,促使他们使用活检或成像来验证诊断。这是一种事后处理办法。我们的研究将集中在癌症检测的表观遗传学信息,特别是癌症不一致的单卵双生子对中人类外周血样本中的DNA甲基化信息。这些信息可能有助于我们在第一个症状出现之前更早地发现癌症。也可以使用其他几种类型的表观遗传数据,但在这里,我们使用SAS 9.3和SAS EM证明了血液DNA甲基化数据作为泛癌症生物标志物的潜力。我们报告了血液样本中可测量的55个甲基化CpG位点可用作早期癌症检测和分类的生物标志物。
英文摘要:
A key focus in current cancer research is the discovery of cancer biomarkers that allow earlier detection with high accuracy and lower costs for both patients and hospitals. Blood samples have long been used as a health status indicator, but DNA methylation signatures in blood have not been fully appreciated in cancer research. Historically, analysis of cancer has been conducted directly with the patient's tumor or related tissues. Such analyses allow physicians to diagnose a patient's health and cancer status; however, physicians must observe certain symptoms that prompt them to use biopsies or imaging to verify the diagnosis. This is a post-hoc approach. Our study will focus on epigenetic information for cancer detection, specifically information about DNA methylation in human peripheral blood samples in cancer discordant monozygotic twin-pairs. This information might be able to help us detect cancer much earlier, before the first symptom appears. Several other types of epigenetic data can also be used, but here we demonstrate the potential of blood DNA methylation data as a biomarker for pan-cancer using SAS 9.3 and SAS EM. We report that 55 methylation CpG sites measurable in blood samples can be used as biomarkers for early cancer detection and classification.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。